The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Noam Barda, Michal Canetti, Mayan Gilboa, Keren Asraf, Victoria Indenboim, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zubli, Ram Doolman, Ella Mendelson, Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.

Original languageEnglish
Pages (from-to)1315-1317
Number of pages3
JournalClinical Infectious Diseases
Volume76
Issue number7
DOIs
StatePublished - 1 Apr 2023

Funding

FundersFunder number
Nehemia Rubin Excellence in Biomedical Research
TELEM Program of Chaim, Sheba Medical Center
Pfizer
Sheba Medical Center

    Keywords

    • IgG levels
    • SARS-CoV-2
    • boosters
    • infection risk
    • mRNA vaccines

    Fingerprint

    Dive into the research topics of 'The Association between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection'. Together they form a unique fingerprint.

    Cite this